BR112017012102A2 - processo para formular uma vacina bacteriana oral estabilizada com ácido - Google Patents

processo para formular uma vacina bacteriana oral estabilizada com ácido

Info

Publication number
BR112017012102A2
BR112017012102A2 BR112017012102-6A BR112017012102A BR112017012102A2 BR 112017012102 A2 BR112017012102 A2 BR 112017012102A2 BR 112017012102 A BR112017012102 A BR 112017012102A BR 112017012102 A2 BR112017012102 A2 BR 112017012102A2
Authority
BR
Brazil
Prior art keywords
formulating
acid
bacterial vaccine
oral bacterial
stabilized oral
Prior art date
Application number
BR112017012102-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Gill Davinder
Sikriwal Deepa
Joshi Neeraj
Saigal Nitin
Sharma Tarun
Kanchan Vibhu
Israel Zimra
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Publication of BR112017012102A2 publication Critical patent/BR112017012102A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR112017012102-6A 2014-12-31 2015-12-29 processo para formular uma vacina bacteriana oral estabilizada com ácido BR112017012102A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4054/DEL/2014 2014-12-31
PCT/IB2015/060022 WO2016108180A2 (en) 2014-12-31 2015-12-29 Process for formulating acid stabilized oral bacterial vaccine
IN4054DE2014 IN2014DE04054A (ko) 2014-12-31 2015-12-29

Publications (1)

Publication Number Publication Date
BR112017012102A2 true BR112017012102A2 (pt) 2018-01-23

Family

ID=56285110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012102-6A BR112017012102A2 (pt) 2014-12-31 2015-12-29 processo para formular uma vacina bacteriana oral estabilizada com ácido

Country Status (6)

Country Link
KR (1) KR20170102253A (ko)
CN (1) CN106999563A (ko)
BR (1) BR112017012102A2 (ko)
IN (1) IN2014DE04054A (ko)
RU (1) RU2017122801A (ko)
WO (1) WO2016108180A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
BR112014024159A2 (pt) * 2012-03-29 2017-06-20 Therabiome Llc Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.

Also Published As

Publication number Publication date
IN2014DE04054A (ko) 2016-07-08
RU2017122801A3 (ko) 2018-12-28
KR20170102253A (ko) 2017-09-08
RU2017122801A (ru) 2018-12-28
WO2016108180A2 (en) 2016-07-07
WO2016108180A3 (en) 2016-09-09
CN106999563A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
CL2018001189A1 (es) Oligonucleótidos para inducir la expresión paterna de ube3a
NZ704584A (en) Liquid stable virus vaccines
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
ECSP17045737A (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
WO2018039475A8 (en) Use of pridopidine for treating dystonias
PH12016502003A1 (en) Novel bacteriophage and composition containing same
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112017013238A2 (pt) bacteriófago esc-cop-1 de e. coli do tipo f18 produtora de toxina shiga inovador e uso do mesmo para a inibição de proliferação de e. coli do tipo f18 produtora de toxina shiga
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
BR102014009838B8 (pt) Método para produzir um l-aminoácido
MX2017016401A (es) Composiciones inmunogenas.
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
UA114997C2 (uk) Рекомбінантний мікроорганізм з роду escherichia, що виробляє l-амінокислоту, та спосіб одержання l-амінокислоти
BR112017012102A2 (pt) processo para formular uma vacina bacteriana oral estabilizada com ácido
BR112018074107A2 (pt) método para a redução da contaminação de ovos
BR112016018257A2 (pt) método para produzir um l-aminoácido
BR112016012036A2 (pt) prevenção da diarréia pela escherichia coli
BR112017009501A2 (pt) método para tratar uma infecção por hcv, método para curar uma infecção por hcv, e, composição farmacêutica.
BR112017009504A2 (pt) métodos para tratar e para curar uma infecção por hcv, e, composição farmacêutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2546 DE 22-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notice of approval relating to section 229 industrial property law